Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc       US6285301072

End-of-day quote. End-of-day quote Nasdaq - 03/04
55.605 USD   +0.31%
05/27DJTeva Reports Small Stake in Mylan
05/27DJTeva Reports Small Stake in Mylan
05/26 MYLAN NV : to Present at the Bernstein Strategic Decisions Conferenc..
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Seeks To Overturn FDA's Provigil Decision

04/05/2012 | 01:10pm US/Eastern

Mylan Inc. (>> Mylan Inc.) said it is seeking to overturn a decision by the U.S. Food and Drug Administration that awarded Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) exclusivity for its generic version of Cephalon Inc.'s wakefulness drug Provigil.

The generic drug maker said Thursday it has filed a lawsuit against the FDA in the U.S. district court for the District of Columbia. Mylan is seeking an immediate court order entitling it to exclusivity as well as immediate approval for its abbreviated new drug application.

Mylan alleges Teva did not maintain valid certifications as a result of its acquisition last year of Cephalon and thus is not entitled to exclusivity based on patent certifications. Mylan also alleges that the FDA should have found Mylan as the sole first filer on one of the patents for Provigil.

Earlier Thursday, Teva said the FDA has decided that Teva is the sole first-to-file for both of Provigil's patents, which entitled the company to 180-day exclusivity. The FDA decided that Cephalon's launch of generic Provigil on March 29 triggered the exclusivity.

In October, the Federal Trade Commission required Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant in connection with Teva's acquisition of Cephalon. The FTC agreement also required Teva to enter a supply agreement that allows a competing firm, Par Pharmaceuticals Inc. (PRX), to sell a generic version of Provigil in 2012.

Teva expects Par Pharmaceuticals to launch a second generic product on April 6.

Mylan shares slipped 1.8% to $22.74 in recent trading. The stock is up 5.9% so far this year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Mylan Inc.
React to this article
Latest news on MYLAN INC
05/27DJTeva Reports Small Stake in Mylan
05/27DJTeva Reports Small Stake in Mylan
05/26 MYLAN NV : to Present at the Bernstein Strategic Decisions Conference
05/21DJLaw Firm Advising Teva Dismisses Mylan Objections
05/21DJLaw Firm Advising Teva on Bid Dismisses Mylan's Objections to Its Involvement
05/18 Endo pushes further into generics with $8 billion Par Pharma buy
05/12 MYLAN NV : to Present at the UBS Global Healthcare Conference
05/12DJPerrigo to Buy Patheon's Mexican Business
05/12DJPerrigo to Buy Patheon's Mexican Business for $34 Million
05/12 MYLAN NV : to Present at the Bank of America Merrill Lynch Health Care Conferenc..
Advertisement
Chart
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Income Statement Evolution
More Financials